Vol 7, No 2 (April 29, 2018): Chinese Clinical Oncology (Cancer Immunotherapy)

Preface

Cancer immunotherapy—the end of the beginning
Han Chong Toh
Chinese Clinical Oncology  
2018;
7
(2)
:12
.

Review Article

What is the role of immunotherapy in breast cancer
Tira J. Tan, Jack J. Chan, Sulastri Kamis, Rebecca Alexandra Dent
Chinese Clinical Oncology  
2018;
7
(2)
:13
.
Emerging role of immunotherapy for childhood cancers
Rupert Handgretinger, Patrick Schlegel
Chinese Clinical Oncology  
2018;
7
(2)
:14
.
Combinatorial strategies of radiotherapy and immunotherapy in nasopharyngeal carcinoma
Eugenia L. L. Yeo, You Quan Li, Khee-Chee Soo, Joseph T. S. Wee, Melvin L. K. Chua
Chinese Clinical Oncology  
2018;
7
(2)
:15
.
The emerging role of oncolytic virus therapy against cancer
Luke Russell, Kah-Whye Peng
Chinese Clinical Oncology  
2018;
7
(2)
:16
.
The evolving role of immune oncology in colorectal cancer
Shaheenah Dawood
Chinese Clinical Oncology  
2018;
7
(2)
:17
.

Editorial

Onward and upward for immuno-oncology
Malcolm K. Brenner
Chinese Clinical Oncology  
2018;
7
(2)
:18
.

Perspective

Immunoregulatory antigens—novel targets for cancer immunotherapy
Ayako Wakatsuki Pedersen, Katharina L. Kopp, Mads Hald Andersen, Mai-Britt Zocca
Chinese Clinical Oncology  
2018;
7
(2)
:19
.
Developing academic cancer immunotherapy in Asia—lessons, challenges, and a vision for Thailand
Nattiya Hirankarn
Chinese Clinical Oncology  
2018;
7
(2)
:20
.
Chimeric antigen receptor T cells, a savior with a high price
Gilberto de Lima Lopes, George R. Nahas
Chinese Clinical Oncology  
2018;
7
(2)
:21
.

Disclosure:

The focused issue “Cancer Immunotherapy” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding. Han Chong Toh served as the unpaid Guest Editor for the focused issue.